China · Delayed Price · Currency is CNY Bide Pharmatech Statistics
Total Valuation
Bide Pharmatech has a market cap or net worth of CNY 5.34 billion. The enterprise value is 4.42 billion.
| Market Cap | 5.34B |
| Enterprise Value | 4.42B |
Important Dates
The next estimated earnings date is Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Bide Pharmatech has 86.15 million shares outstanding. The number of shares has decreased by -2.03% in one year.
| Current Share Class | 86.15M |
| Shares Outstanding | 86.15M |
| Shares Change (YoY) | -2.03% |
| Shares Change (QoQ) | +3.45% |
| Owned by Insiders (%) | 51.61% |
| Owned by Institutions (%) | 17.09% |
| Float | 26.51M |
Valuation Ratios
The trailing PE ratio is 35.39 and the forward PE ratio is 35.09.
| PE Ratio | 35.39 |
| Forward PE | 35.09 |
| PS Ratio | 4.20 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | 135.24 |
| P/OCF Ratio | 80.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.03, with an EV/FCF ratio of 112.10.
| EV / Earnings | 28.85 |
| EV / Sales | 3.48 |
| EV / EBITDA | 21.03 |
| EV / EBIT | 24.45 |
| EV / FCF | 112.10 |
Financial Position
The company has a current ratio of 4.56, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.56 |
| Quick Ratio | 2.73 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 1.12 |
| Debt / FCF | 5.99 |
| Interest Coverage | 48.78 |
Financial Efficiency
Return on equity (ROE) is 7.66% and return on invested capital (ROIC) is 12.88%.
| Return on Equity (ROE) | 7.66% |
| Return on Assets (ROA) | 4.60% |
| Return on Invested Capital (ROIC) | 12.88% |
| Return on Capital Employed (ROCE) | 8.85% |
| Weighted Average Cost of Capital (WACC) | 8.35% |
| Revenue Per Employee | 1.72M |
| Profits Per Employee | 207,732 |
| Employee Count | 129 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 0.91 |
Taxes
In the past 12 months, Bide Pharmatech has paid 51.89 million in taxes.
| Income Tax | 51.89M |
| Effective Tax Rate | 25.29% |
Stock Price Statistics
The stock price has increased by +20.22% in the last 52 weeks. The beta is 0.80, so Bide Pharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | +20.22% |
| 50-Day Moving Average | 67.69 |
| 200-Day Moving Average | 61.01 |
| Relative Strength Index (RSI) | 40.66 |
| Average Volume (20 Days) | 1,289,451 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bide Pharmatech had revenue of CNY 1.27 billion and earned 153.31 million in profits. Earnings per share was 1.75.
| Revenue | 1.27B |
| Gross Profit | 522.79M |
| Operating Income | 180.89M |
| Pretax Income | 205.19M |
| Net Income | 153.31M |
| EBITDA | 192.75M |
| EBIT | 180.89M |
| Earnings Per Share (EPS) | 1.75 |
Balance Sheet
The company has 1.15 billion in cash and 236.14 million in debt, with a net cash position of 913.03 million or 10.60 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 236.14M |
| Net Cash | 913.03M |
| Net Cash Per Share | 10.60 |
| Equity (Book Value) | 2.00B |
| Book Value Per Share | 23.24 |
| Working Capital | 1.85B |
Cash Flow
In the last 12 months, operating cash flow was 66.50 million and capital expenditures -27.04 million, giving a free cash flow of 39.45 million.
| Operating Cash Flow | 66.50M |
| Capital Expenditures | -27.04M |
| Free Cash Flow | 39.45M |
| FCF Per Share | 0.46 |
Margins
Gross margin is 41.17%, with operating and profit margins of 14.25% and 12.07%.
| Gross Margin | 41.17% |
| Operating Margin | 14.25% |
| Pretax Margin | 16.16% |
| Profit Margin | 12.07% |
| EBITDA Margin | 15.18% |
| EBIT Margin | 14.25% |
| FCF Margin | 3.11% |
Dividends & Yields
This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 1.54%.
| Dividend Per Share | 0.90 |
| Dividend Yield | 1.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 51.65% |
| Buyback Yield | 2.03% |
| Shareholder Yield | 3.54% |
| Earnings Yield | 2.87% |
| FCF Yield | 0.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 25, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | May 25, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Bide Pharmatech has an Altman Z-Score of 6.54 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.54 |
| Piotroski F-Score | 5 |